Sophia Genetics Sa · NASDAQ:SOPH

Sophia Genetics Sa — Investor Presentation (May 2023)

21 slides from Sophia Genetics Sa's investor presentation, May 12, 2023

  1. Slide 1: Building a Data-Driven World

    Building a Data - Driven World Dr. Jurgi CAMBLONG Chief Executive Officer & Co - Founder May 12, 2023

  2. Slide 2: Cautionary Notices

    Cautionary Notices This presentation contains statements that constitute forward - looking statements . All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategy,

  3. Slide 3: Snapshot of SOPHiA Genetics

    © SOPHiA GENETICS 2023 3 Snapshot of SOPHiA Genetics

  4. Slide 4: The Emergence of the Cloud and AI have transformed countless industries

    © SOPHiA GENETICS 2023 4 The Emergence of the Cloud and AI have transformed countless of industries Financial Services Human Resources IT Security Supply Chain Retail BUT, He a l t h c a r e is lagging

  5. Slide 5: Healthcare Data are Complex, Siloed and Diverse

    © SOPHiA GENETICS 2023 Healthcare Data are Complex, Siloed and Diverse 5

  6. Slide 6: Creating Network Effects in Healthcare is Difficult

    © SOPHiA GENETICS 2023 Creating Network Effects in Healthcare is Difficult given non - standardized methods and sensitive data 6

  7. Slide 7: Collective Intelligence All-in-One Platform

    © SOPHiA GENETICS 2023 Collective Intelligence all - in - One Platform to better and equally serve every patient around the world Machine Learning T e c h n olo g y A g n osti c 7 Artificial I n te ll i g e n c e Continual Learning 1,000,000+ Analyses

  8. Slide 8: Significantly Important for Key Diseases driven by genomic alterations

    8 1. by 2040, 2 . https:// www.rarediseasesinternational.org/ Cancer >25 Million New Cancer Cases per Year 1 Rare Diseases ~5% of the global population suffers from a Rare Disease 2 Significantly Important for Key Diseases driven by genomic alterations

  9. Slide 9: Multimodal Data Brings Objectivity into human biology and diseases

    © SOPHiA GENETICS 2023 Multimodal Data Brings Objectivity into human biology and diseases

  10. Slide 10: Empowering Clinical and BioPharma Customers

    Empowering Clinical and BioPharma Customers driving the data flywheel to benefit patients Discovery Apply benefits of proprietary AI/ ML to late - stage discovery phases Development Comprehensive suite of applications backed by AI - based algorithms to aid in harmonization and reporting Deployment E

  11. Slide 11: Transforming Healthcare through Strategic Collaborations

    Transforming Healthcare through Strategic Collaborations 11 » Generate robust insights » Break data silos » Create a collective intelligence » Accelerate adoption of precision medicine

  12. Slide 12: Total Addressable Market is Significant

    © SOPHiA GENETICS 2023 Total Addressable Market is Significant 12 FN As of March 31, 2023

  13. Slide 13: Clinical TAM Supported by a Broad Set of Disease Indications

    © SOPHiA GENETICS 2023 Clinical TAM Supported by a Broad Set of Disease Indications 13 Disease Indications Somatic Oncology Liquid Biopsy He m O n c Hereditary Cancers Rare and Inherited Disorders FN As of March 31, 2023

  14. Slide 14: Growing with our Customers

    Growing with our Customers Volume 14 Central Labs © SOPHiA GENETICS 2023 C o m p r e h e n s i v e Cancer Centers Specialty Labs University Hospitals In - House Sequencing SOPHiA Patented Algorithms 1 C o n s u m p t i o n based model Interpret Data Targeted Clinical Outcomes Clinical Re p o r t i n

  15. Slide 15: BioPharma TAM is an Emerging Opportunity

    BioPharma TAM is an Emerging Opportunity 15 Discovery Applying AI and ML to the proprietary data of our customers Development Powering predictive aalgorithms for better targeted drugs Deployment Entering markets worldwide with new solutions via our network

  16. Slide 16: Key Financial Metrics

    750+ Total customers (1) 430+ Core Genomics customers (1) 1.2 million+ Genomic Profiles Analyzed (1) ~77,000+ Genomic profiles analyzed in 1Q 2023 (1) 30% - 35% 2023 constant currency ex COVID revenue growth guidance (2) 37% 1Q2023 constant currency ex COVID revenue growth (2) 69% | 73% Q1 2023 IFRS

  17. Slide 17: Thank You

    2*- SOPHIA Thank You ° of eNerce

  18. Slide 18: Reconciliation of IFRS to Adjusted Gross Profit and Gross Profit Margin

    Amounts in USD thousands (unaudited) Three months ended March 31, 2023 Revenue $13,966 Cost of revenue ( 4 , 272 ) Gross profit $9,694 Amortization of capitalized research and development expenses (1) 432 Adjusted gross profit $10,126 Gross profit margin 69% Amortization of capitalized research and

  19. Slide 19: Reconciliation of IFRS Revenue Growth to Constant Currency Revenue Growth

    © SOPHiA GENETICS 2023 Reconciliation of IFRS Revenue Growth to Constant Currency Revenue Growth and Constant Currency Revenue Growth Excluding COVID - 19 - Related Revenue 19 Source: SOPH FY 2022 6 - K: https:// www.sec.gov/Archives/edgar/data/1840706/000184070623000008/sophiageneticssaq42022.htm S

  20. Slide 20: Notes to the Reconciliation of IFRS to Adjusted Financials

    © SOPHiA GENETICS 2023 20 Notes to the Reconciliation of IFRS to Adjusted Financials (1) Amortization of capitalized research and development expenses consists of software development costs amortized using the straight - line method over an estimated life of five years. These expenses do not have a

  21. Slide 21: Consistent Growth in Analysis Volume

    © SOPHiA GENETICS 2023 Consistent Growth in Analysis Volume accelerated momentum of analysis volume conducted on our platform going into 2023 21 COVID - 19 Analyses Total Analyses 2017 2018 2019 2020 Core Genomics Analyses (1) 2021 2022 2023 6k 11k 10k 8k 5k 6k 5k 3k 2k 17k 19k 19k 26k 27k 29k 29k 3

SOPHiA GENETICS — Investor Presentation (May 2023) on 6ix